Red X iconGreen tick iconYellow tick icon

Contact Details

Clinical Senior Lecturer
Department of Pathology and Biomedical Science (Christchurch)
BM BCh(Oxford) MA PhD(Cambridge) FRACP FRCPA
Research summary


Dr Ganly's expertise and interests include the diagnosis and management of malignant haematological diseases, stem cell transplantation and clinical research.


Hillmen, P., Eichhorst, B., Brown, J. R., Lamanna, N., O'Brien, S. M., Tam, C. S., … Ganly, P. S., Weinkove, R., … Jurczak, W. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomised phase III trial. Journal of Clinical Oncology, 41(5), 1035-1045. doi: 10.1200/JCO.22.00510 Journal - Research Article

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., … Ganly, P. S., Weinkove, R., … Shadman, M. (2023). Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. New England Journal of Medicine, 388, 319-332. doi: 10.1056/NEJMoa2211582 Journal - Research Article

Brown, J. R., Hillmen, P., Eichhorst, B., Lamanna, N., O'Brien, S., Tam, C., … Ganly, P. S., … Jurczak, W. (2022). First interim analysis of ALPINE Study: Results of a phase 3 randomized study of Zanubrutinib vs Ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Clinical Lymphoma & Myeloma, 22(Suppl. 2), (pp. S266). doi: 10.1016/S2152-2650(22)01324-6 Conference Contribution - Published proceedings: Abstract

Tam, C. S., Robak, T., Ghia, P., Kahl, B. S., Walker, P., Janowski, W., … Ganly, P. S., … Brown, J. R. (2021). Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. Haematologica, 106(9), 2354-2363. doi: 10.3324/haematol.2020.259432 Journal - Research Article

Richardson, P. G., Kumar, S. K., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., … Ganly, P., … Moreau, P. (2021). Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 39(22), 2430-2442. doi: 10.1200/JCO.21.00972 Journal - Research Article

Back to top